Pangea Biomed
Haifa, Israel· Est.
AI‑driven multi‑omics platform that predicts personalized cancer therapies and accelerates drug discovery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven multi‑omics platform that predicts personalized cancer therapies and accelerates drug discovery.
Oncology
Technology Platform
ENLIGHT integrates multi‑omics (expression, epigenetics, proteomics) with AI‑driven inference of genetic interaction networks to predict tumor vulnerabilities and personalized treatment responses.
Opportunities
Broad adoption of ENLIGHT by pharma and academic partners could drive revenue through licensing, collaborative drug‑development projects, and companion‑diagnostic services.
Risk Factors
Reliance on AI‑based predictions may face regulatory scrutiny and require extensive clinical validation; competition from established genomics‑analytics firms could limit market penetration.
Competitive Landscape
Key competitors include Tempus, Foundation Medicine and IBM Watson for Oncology; Pangea differentiates itself by focusing on functional gene‑interaction networks and multi‑omics integration beyond simple mutation profiling.